NCT00360763UnknownPhase 4
Study of Optimal Treatment Plan in Hypertensives With Anti-AT1-Receptor Autoantibody
Huazhong University of Science and Technology1 site in 1 country600 target enrollmentStarted: August 7, 2006Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 4
- Enrollment
- 600
- Locations
- 1
Study Overview
Brief Summary
The autoantibodies against AT1 receptor (ATR-AA), behaving like an agonist were detected in patients with hypertension. ATR-AA which can blocked by ARB may play a role in the pathogenesis of hypertension. The present study is to explore whether AT1 receptor blocker has superior anti-hypertensive effect in patients with positive ATR-AA hypertension. Patients with 2 grade hypertension were recruited and ATR-AA was assayed by ELISA. A study was carried out and the efficacy of anti-hypertension was compared between candesartan cilexetil and ACE inhibitor imidapril.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Hypertension (2 grade)
Exclusion Criteria
- •Secondary hypertension
- •Known sensitivity or intolerance to an angiotensin II receptor antagonist or ACE inhibitor
- •Pregnancy
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
Anti-Angiotensin-Receptor 1 (ATR1)-, Anti-Endothelin-Receptor A (ETRA)-Antibodies and T Cells in CardiomyopathyCardiac FailureNCT02319590Zurich Regional Health Center80
Unknown
Not Applicable
Angiotensin-II Receptor Antibodies Blockade With Losartan in Patients With Lupus NephritisLupus NephritisAtherosclerosisNCT03526042Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran40
Unknown
Not Applicable
Clinical One-stage Controlled Study of reSistant Arterial Hypertension for the desiGning of a personAlized Approach to TherapyResistant Arterial HypertensionNCT05899920Ryazan State Medical University190
Terminated
Not Applicable
Analysis of Antihypertensive Treatment EfficacyArterial HypertensionNCT00767247AstraZeneca2,000
Withdrawn
Phase 3
Mechanism of Masked Hypertension - InterventionMasked HypertensionNCT04121299University of Alabama at Birmingham